• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Country Report: China


Pharmaceutical Executive

Pharmaceutical ExecutivePharmaceutical Executive-09-01-2019
Volume 39
Issue 9

A decade into China’s far-reaching healthcare reforms-which began with the implementation of universal, albeit rudimentary, medical insurance-the pace of change and transformation within the country’s life sciences industry shows no signs of abating.

Let a Hundred Flowers Bloom

China's meteoric rise as an economic and political power on the global stage dominates discourse today. While the "Middle Kingdom" is reclaiming global attention, an equally remarkable story of transformation is coalescing within the country's healthcare and life sciences industry. A decade into China's far-reaching healthcare reforms, which began in 2009 with the implementation of universal, albeit rudimentary, medical insurance, the furious pace of change shows no signs of abating.

Since the State Council issued the Healthy China 2030 blueprint in October 2016, China has forged its own path toward the Holy Trinity of access, affordability, and innovation. A cascade of reforms and policies aimed at aligning China with the best practices of the global industry while accommodating the exceptional needs of the Chinese market is steadily shaping a new healthcare system with Chinese characteristics. 


To view the full article on China's healthcare and life sciences markets, produced by Focus Reports and featured in Pharm Exec's September 2019 issue, click 


 (cycle down to page 42).

To preview and purchase other in-depth global Phama Reports, highlighting several countries and emerging markets, please visit www.industrymatter.com/reports

Related Videos
Related Content